Intercept rollercoaster continues with NASH, PBC updates

Intercept Pharmaceuticals fell 30.1% to $172.59 per share on 7 November after data from the Phase II FLINT clinical trial for obeticholic acid (OCA) were published in The Lancet, but the update provided little new information about the drug's safety and efficacy in non-alcoholic steatohepatitis (NASH).

Intercept Pharmaceuticals fell 30.1% to $172.59 per share on 7 November after data from the Phase II FLINT clinical trial for obeticholic acid (OCA) were published in The Lancet, but the update provided little new information about the drug's safety and efficacy in non-alcoholic steatohepatitis (NASH).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

01 May 2025

• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

25 Apr 2025

• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

Sebela’s Tegoprazan Poised For GERD Market

23 Apr 2025

• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

22 Apr 2025

• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.